# VARS1

## Overview
The VARS1 gene encodes the enzyme valyl-tRNA synthetase 1, which is a member of the aminoacyl-tRNA synthetases (ARSs) family. This enzyme is crucial for protein synthesis, as it catalyzes the attachment of the amino acid valine to its corresponding tRNA, a process known as aminoacylation. This function is essential for the accurate translation of genetic information into proteins, thereby maintaining cellular protein homeostasis (HIZ2022VARS1). The VARS1 protein is characterized by several domains, including a glutathione S-transferase C-terminal domain, a tRNA synthetase class 1 domain, an anticodon-binding domain, and a coiled coil domain, which are integral to its function (HIZ2022VARS1). Mutations in the VARS1 gene have been linked to severe neurodevelopmental disorders, underscoring its importance in normal brain development and function (Friedman2019Biallelic).

## Structure
The VARS1 protein, encoded by the human VARS1 gene, is a valyl-tRNA synthetase involved in protein synthesis. It is composed of several domains, including a glutathione S-transferase C-terminal domain, a tRNA synthetase class 1 domain, an anticodon-binding domain, and a coiled coil domain (HIZ2022VARS1). The anticodon-binding domain is particularly significant, as it contains a helix-turn-helix motif crucial for the enzyme's function (HIZ2022VARS1).

The primary structure of VARS1 includes a sequence of amino acids that form these domains. The secondary structure features alpha helices and beta sheets, which contribute to the protein's overall stability and function. The tertiary structure of VARS1 results in a three-dimensional conformation necessary for its enzymatic activity, particularly in recognizing and binding tRNA (FUKAI2003Mechanism).

The VARS1 protein may also exhibit a quaternary structure when forming complexes with other proteins, although specific details on this aspect are not provided in the context. The protein's structure is further characterized by its ability to interact with tRNA through specific molecular interactions, such as those involving the α-helix bundle domain and the coiled-coil domain, which stabilize the tRNA during aminoacylation (FUKAI2003Mechanism).

## Function
The VARS1 gene encodes valyl-tRNA synthetase 1, an enzyme that plays a critical role in protein synthesis by catalyzing the attachment of the amino acid valine to its corresponding tRNA. This process, known as aminoacylation, is essential for the accurate translation of genetic information into proteins, ensuring high fidelity in protein production (HIZ2022VARS1). VARS1 is part of the aminoacyl-tRNA synthetases (ARSs) family, which are housekeeping enzymes ubiquitously expressed in all cells and are crucial for maintaining cellular protein homeostasis (HIZ2022VARS1).

In healthy human cells, VARS1 operates in the cytoplasm, where it is involved in the translation machinery, facilitating the proper incorporation of valine into proteins. This function is vital for various cellular processes and overall organismal growth and function (HIZ2022VARS1). The enzyme consists of several domains, including the anticodon-binding domain, which is responsible for recognizing and binding the appropriate tRNA, ensuring the correct attachment of valine (HIZ2022VARS1). The structural integrity of these domains is crucial for the enzyme's role in protein synthesis, and any mutations affecting these domains can lead to destabilizing effects and impair normal brain development and function (HIZ2022VARS1).

## Clinical Significance
Mutations in the VARS1 gene, which encodes the valyl-tRNA synthetase enzyme, are associated with a severe neurodevelopmental disorder known as progressive neurodevelopmental epileptic encephalopathy. This condition is characterized by symptoms such as global developmental delay, severe epilepsy, hypsarrhythmia, acquired microcephaly, and cortical atrophy, typically manifesting in the first weeks to months of life. Affected individuals often do not survive past childhood due to medical complications (Friedman2019Biallelic).

The mutations in VARS1 are typically missense variants that disrupt highly conserved residues in the tRNA binding domain and adjacent to the anticodon domain, leading to reduced enzymatic activity despite the presence of intact VARS protein in patient cells (Friedman2019Biallelic). These mutations result in a partial loss of function, impacting the ability to bind tRNA and transfer charged valine, which is crucial for protein synthesis (Friedman2019Biallelic).

Research using models such as zebrafish has recapitulated key neurological disease traits, providing insights into the genetic and biological underpinnings of these disorders (Siekierska2019Biallelic). The study of VARS1 mutations highlights the critical role of aminoacyl-tRNA synthetases in neurodevelopment and suggests potential avenues for developing precision therapies (Siekierska2019Biallelic).

## Interactions
VARS1, or valyl-tRNA synthetase 1, is involved in several interactions with other proteins and nucleic acids. It is a component of the multi-tRNA synthetase complex (MSC) in mammals, which includes eight cytoplasmic aminoacyl-tRNA synthetases and three auxiliary proteins. This complex enhances aminoacylation by forming stable associations with tRNAs and serves as a reservoir for components with noncanonical functions. VARS1 specifically forms a complex with the heavy form of elongation factor 1 (EF-1H) to enhance the aminoacylation of tRNA Val, facilitating the transfer of aminoacyl-tRNA to the ribosome (Kong2020Cell‐based).

In the context of melanoma, VARS1 has been identified as a hub gene in a protein-protein interaction network related to M2-like tumor-associated macrophage infiltration. This network was constructed using the STRING database, and VARS1 was identified as a key gene through various algorithms in the Cytoscape cytoHubba plugin (Wu2022Transcriptomebased). These interactions suggest that VARS1 plays a significant role in both protein synthesis and immune regulation, potentially impacting melanoma progression and immunotherapy efficacy.


## References


[1. (FUKAI2003Mechanism) SHUYA FUKAI, OSAMU NUREKI, SHUN-ICHI SEKINE, ATSUSHI SHIMADA, DMITRY G. VASSYLYEV, and SHIGEYUKI YOKOYAMA. Mechanism of molecular interactions for trnaval recognition by valyl-trna synthetase. RNA, 9(1):100–111, January 2003. URL: http://dx.doi.org/10.1261/rna.2760703, doi:10.1261/rna.2760703. This article has 55 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1261/rna.2760703)

[2. (Kong2020Cell‐based) Jiwon Kong and Sunghoon Kim. Cell‐based analysis of pairwise interactions between the components of the multi‐trna synthetase complex. The FASEB Journal, 34(8):10476–10488, June 2020. URL: http://dx.doi.org/10.1096/fj.202000418R, doi:10.1096/fj.202000418r. This article has 5 citations.](https://doi.org/10.1096/fj.202000418R)

[3. (Friedman2019Biallelic) Jennifer Friedman, Desiree E. Smith, Mahmoud Y. Issa, Valentina Stanley, Rengang Wang, Marisa I. Mendes, Meredith S. Wright, Kristen Wigby, Amber Hildreth, John R. Crawford, Alanna E. Koehler, Shimul Chowdhury, Shareef Nahas, Liting Zhai, Zhiwen Xu, Wing-Sze Lo, Kiely N. James, Damir Musaev, Andrea Accogli, Kether Guerrero, Luan T. Tran, Tarek E. I. Omar, Tawfeg Ben-Omran, David Dimmock, Stephen F. Kingsmore, Gajja S. Salomons, Maha S. Zaki, Geneviève Bernard, and Joseph G. Gleeson. Biallelic mutations in valyl-trna synthetase gene vars are associated with a progressive neurodevelopmental epileptic encephalopathy. Nature Communications, February 2019. URL: http://dx.doi.org/10.1038/s41467-018-07067-3, doi:10.1038/s41467-018-07067-3. This article has 30 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41467-018-07067-3)

[4. (HIZ2022VARS1) AYŞE SEMRA HIZ, SEVAL KILIÇ, GÜNEY BADEMCİ, TÜLAY KARAKULAK, AYBİKE ERDOĞAN, BURCU ÖZDEN YÜCEL, ÇİĞDEM ERESEN YAZICIOĞLU, ŞERİFE ESRA ERDAL BAĞRIYANIK, ULUÇ YİŞ, MUSTAFA TEKİN, GÖKHAN KARAKÜLAH, EZGİ KARACA EREK, and MEHMET ÖZTÜRK. Vars1 mutations associated with neurodevelopmental disorder are located on a short amino acid stretch of the anticodon-binding domain. Turkish Journal of Biology, 46(6):458–464, January 2022. URL: http://dx.doi.org/10.55730/1300-0152.2631, doi:10.55730/1300-0152.2631. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.55730/1300-0152.2631)

[5. (Siekierska2019Biallelic) Aleksandra Siekierska, Hannah Stamberger, Tine Deconinck, Stephanie N. Oprescu, Michèle Partoens, Yifan Zhang, Jo Sourbron, Elias Adriaenssens, Patrick Mullen, Patrick Wiencek, Katia Hardies, Jeong-Soo Lee, Hoi-Khoanh Giong, Felix Distelmaier, Orly Elpeleg, Katherine L. Helbig, Joseph Hersh, Sedat Isikay, Elizabeth Jordan, Ender Karaca, Angela Kecskes, James R. Lupski, Reka Kovacs-Nagy, Patrick May, Vinodh Narayanan, Manuela Pendziwiat, Keri Ramsey, Sampathkumar Rangasamy, Deepali N. Shinde, Ronen Spiegel, Vincent Timmerman, Sarah von Spiczak, Ingo Helbig, Chris Balak, Newell Belnap, Ana Claasen, Amanda Courtright, Matt de Both, Matthew J. Huentelman, Marcus Naymik, Ryan Richholt, Ashley L. Siniard, Szabolcs Szelinger, David W. Craig, Isabelle Schrauwen, Zaid Afawi, Rudi Balling, Stéphanie Baulac, Nina Barišić, Hande S. Caglayan, Dana Craiu, Rosa Guerrero-López, Renzo Guerrini, Helle Hjalgrim, Johanna Jähn, Karl Martin Klein, Eric Leguern, Johannes R. Lemke, Holger Lerche, Carla Marini, Rikke S. Møller, Hiltrud Muhle, Felix Rosenow, Jose Serratosa, Arvid Suls, Ulrich Stephani, Katalin Štěrbová, Pasquale Striano, Federico Zara, Sarah Weckhuysen, Christopher Francklyn, Anthony Antonellis, Peter de Witte, and Peter De Jonghe. Biallelic vars variants cause developmental encephalopathy with microcephaly that is recapitulated in vars knockout zebrafish. Nature Communications, February 2019. URL: http://dx.doi.org/10.1038/s41467-018-07953-w, doi:10.1038/s41467-018-07953-w. This article has 41 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41467-018-07953-w)

[6. (Wu2022Transcriptomebased) Zhengquan Wu, Ke Lei, Huaizhi Li, Jiali He, and Enxian Shi. Transcriptome-based network analysis related to m2-like tumor-associated macrophage infiltration identified vars1 as a potential target for improving melanoma immunotherapy efficacy. Journal of Translational Medicine, October 2022. URL: http://dx.doi.org/10.1186/s12967-022-03686-z, doi:10.1186/s12967-022-03686-z. This article has 11 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s12967-022-03686-z)